Subject-matter of the invention is a process for the preparation of a key intermediate in the synthesis of indacaterol. Subject-matter of the invention are also new synthesis intermediates. Formula (I): ##STR00001##

Subject-matter of the invention is a process for the preparation of a key intermediate in the synthesis of indacaterol. Subject-matter of the invention are also new synthesis intermediates. Formula (I): ##STR00001##

A new process for preparing the fenfluramine molecule and new compositions containing fenfluramine obtainable with the claimed process.

A new process for preparing the fenfluramine molecule and new compositions containing fenfluramine obtainable with the claimed process.

A new process for preparing the fenfluramine molecule and new compositions containing fenfluramine obtainable with the claimed process.

Embodiments of the present disclosure provide for biaryl ligands (also referred to herein as biaryl compound), biaryl complexes, methods of making biaryl compounds, methods of making single enantiomers of these biaryl compounds, methods of use (e.g., catalysis) and the like.

Embodiments of the present disclosure provide for biaryl ligands (also referred to herein as biaryl compound), biaryl complexes, methods of making biaryl compounds, methods of making single enantiomers of these biaryl compounds, methods of use (e.g., catalysis) and the like.

The present invention relates to compounds of the formula (I) and in particular to medicaments comprising at least one compound of the formula (I) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions in the triggering of which cathepsin D is involved, in particular for use in the treatment and/or prophylaxis of osteoarthritis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia.

The present invention relates to compounds of the formula (I) and in particular to medicaments comprising at least one compound of the formula (I) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions in the triggering of which cathepsin D is involved, in particular for use in the treatment and/or prophylaxis of osteoarthritis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia.

Catalyst systems and methods for making and using the same are provided. A method for forming a polymer catalyst includes reacting a bromoketone compound with an aryl amine compound to form an amide compound. The amide compound is reacted with an ethylene diamine compound, to form a terminal primary amine compound. The terminal primary amine compound is reacted with a bromoaryl compound to form a ligand.